Cytokinetics

Cardiac and skeletal muscle biology, myosin modulators

CYTK · Nasdaq · United States

Share price · CYTK

$51.32-24.78 (-32.56%) 3M

close as of 2026-11-18 · 24h delayed · vol 1.6M (0.8x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when CYTK's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 5 Nov 2026-12.7%
  2. 5 Oct 2026-4.4%
  3. 8 Sep 2026+3.6%
  4. 7 Aug 2026-5.7%
  5. 16 Jun 2026+5.4%

    Nothing announced by CYTK that day or the session before.

  6. 5 May 2026+16.7%
  7. 30 Apr 2026+7.4%

    Nothing announced by CYTK that day or the session before.

  8. 27 Apr 2026-5.7%

    Nothing announced by CYTK that day or the session before.

  9. 25 Feb 2026-10.3%
  10. 18 Dec 2025+4.0%

    Nothing announced by CYTK that day or the session before.

Share of unusual movement by asset

For each asset, the share of CYTK's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Aficamten (Myqorzo)
events and moves
168%
Other company news (earnings, financing, releases naming no asset)—47%
Sessions with no dated event—45%

Assets

(4 total)
4Total Assets
1Approved
1Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
Showing 4 of 4 assets
Target & Modality
Aficamten(Myqorzo)
Approved
Cardiac myosin (inhibitor)Small molecule
Hypertrophic Cardiomyopathy
Phase 3
Cardiac myosin (activator)Small molecule
Heart Failure
Heart Failure with Reduced Ejection Fraction
Phase 2
Cardiac myosin (inhibitor)Small molecule
Heart Failure
Heart Failure with Preserved Ejection Fraction
TirasemtivNo recent activity
Discontinued
Troponin complex (skeletal muscle fast fibers)
Indication not yet linked

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
September 2027 (1)
Omecamtiv mecarbilPhase 3Heart Failure, Heart Failure With Reduced Ejection Fraction
Est. primary completion 2027-09 · NCT06736574 · CT.gov ↗
What to watch
2029 (1)
March 2029 (1)
Aficamten · MyqorzoPhase 2/3Symptomatic Hypertrophic Cardiomyopathy (HCM)
Est. primary completion 2029-03 · NCT04848506 · CT.gov ↗
What to watch
2030 (1)
January 2030 (1)
Aficamten · MyqorzoPhase 2/3Pediatric, Symptomatic Obstructive Hypertrophic Cardiomyopathy
Est. primary completion 2030-01 · NCT06412666 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

5 May 2026Topline resultAficamtenACACIA-HCM Phase 3 of aficamten in non-obstructive HCM met both dual primary endpoints
Cytokinetics · Source ↗
19 December 2025ApprovalAficamtenFDA Boxed Warning on Myqorzo (NDA219083)
US, FDA · FDA · Source ↗
28 February 2023Complete response letterOmecamtiv mecarbilFDA issues a complete response letter for the omecamtiv mecarbil NDA in HFrEF
US, FDA · Cytokinetics, Incorporated · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$48M$99M$203M+ $927M short-term inv.$190M-$124M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$29M$98M$255M+ $910M short-term inv.$199M-$160M operating cash flowreport ↗
2026-Q1$19M$96M$130M+ $689M short-term inv.$206M-$145M operating cash flowreport ↗
2025-Q3$1.9M$99M$225M+ $737M short-term inv.$306M-$108M operating cash flowreport ↗
2025-Q2$67M$113M$75M+ $783M short-term inv.$134M-$128M operating cash flowreport ↗
2025-Q1$1.6M$100M$74M+ $865M short-term inv.$161M-$132M operating cash flowreport ↗
2024-Q3$0.5M$85M$47M+ $965M short-term inv.$161M-$102M operating cash flowreport ↗
2024-Q2$0.3M$80M$190M+ $867M short-term inv.$143M-$99M operating cash flowreport ↗
2024-Q1$0.8M$82M$120M+ $499M short-term inv.$136M-$130M operating cash flowreport ↗
2023-Q3$0.4M$83M$100M+ $440M short-term inv.$129M-$96M operating cash flowreport ↗
2023-Q2$0.9M$83M$69M+ $497M short-term inv.$129M-$122M operating cash flowreport ↗
2023-Q1$4.6M$79M$102M+ $562M short-term inv.$131M-$122M operating cash flowreport ↗
2022-Q3$2.5M$63M$106M+ $761M short-term inv.$142M-$84M operating cash flowreport ↗
2022-Q2$89M$57M$94M+ $492M short-term inv.$20M-$90M operating cash flowreport ↗
2022-Q1$1.1M$46M$115M+ $494M short-term inv.$89M-$27M operating cash flowreport ↗
2021-Q3$5.4M$48M$91M+ $387M short-term inv.$76M-$39M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$88M$416M$123M+ $760M short-term inv.$196M-$510M operating cash flowreport ↗

For fiscal 2025, Cytokinetics reported total revenue of $88.04M, up 376.7% YoY, and R&D spend of $416.03M, up 22.6% YoY. The company ended the year with approximately $1.22B in cash, cash equivalents and investments, and reported a net loss of $784.95M, with quarterly net burn of $784.96M.

Business developments included MYQORZO approvals in the U.S., China, and Europe, with the U.S. launch underway, and submission of a supplemental NDA for MAPLE-HCM. The company guided 2026 GAAP combined R&D and SG&A expense to $830M-$870M, expects topline results from ACACIA-HCM in Q2 2026, a Germany launch in Q2 2026, and potential FDA approval of the MAPLE-HCM sNDA in Q4 2026.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$18M$339M$95M+ $981M short-term inv.$147M-$396M operating cash flowreport ↗
2023-FY$7.5M$330M$113M+ $502M short-term inv.$132M-$414M operating cash flowreport ↗
2022-FY$95M$241M$66M+ $717M short-term inv.$97M-$300M operating cash flowreport ↗
2021-FY$70M$160M$113M+ $359M short-term inv.$54M-$143M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 90 sales ($52.9M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-17Hessekiel Jeffrey · Chief Legal & Admin OfficerOpen-market sale15,106$52.62$795KForm 4
2026-11-17Malik Fady Ibraham · EVP Research & DevelopmentOption exercise3,500$7.80$27KForm 4
2026-11-17Malik Fady Ibraham · EVP Research & DevelopmentOpen-market sale3,300$51.73$171KForm 4
2026-11-17Malik Fady Ibraham · EVP Research & DevelopmentOpen-market sale200$52.59$11KForm 4
2026-11-17Malik Fady Ibraham · EVP Research & DevelopmentOption exercise (derivative)3,500——Form 4
2026-11-16Blum Robert I · director, President & CEOOption exercise7,500$10.60$80KForm 4
2026-11-16Blum Robert I · director, President & CEOOpen-market sale5,077$53.22$270KForm 4
2026-11-16Blum Robert I · director, President & CEOOpen-market sale2,223$54.08$120KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 435 reporting institutions held 146.2M shares ($8.3B, 117.5% of shares outstanding).

#InstitutionSharesValue
1BlackRock, Inc.16,548,011$1.1B
2FMR LLC10,723,140$706.8M
3WELLINGTON MANAGEMENT GROUP LLP8,009,489$527.9M
4VANGUARD PORTFOLIO MANAGEMENT LLC5,843,782$385.2M
5STATE STREET CORP5,745,193$378.7M
6VANGUARD CAPITAL MANAGEMENT LLC5,488,634$361.8M
7Avoro Capital Advisors LLC3,333,333$219.7M
8GEODE CAPITAL MANAGEMENT, LLC3,215,415$212.0M
9BANK OF AMERICA CORP /DE/3,125,436$206.0M
10RTW INVESTMENTS, LP2,721,158$179.4M
11GOLDMAN SACHS GROUP INC2,205,758$145.4M
12UBS Group AG2,077,277$136.9M
13Polar Capital Holdings Plc1,661,248$109.5M
14Integral Health Asset Management, LLC1,600,000$105.5M
15MORGAN STANLEY1,505,075$99.2M